![Edgar Charles](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Edgar Charles
Hoofd Techniek/Wetenschap/O&O bij
CLIMB BIO, INC.
Profiel
Edgar D.
Charles is Chief Medical Officer at Climb Bio, Inc. since 2025.
Dr. Charles was Vice President at Bristol Myers Squibb Co. from 2015 to 2025.
Dr. Charles completed undergraduate studies at The University of Chicago, graduate studies at The Rockefeller University, and earned a doctorate from The University of Alabama School of Medicine.
Actieve functies van Edgar Charles
| Bedrijven | Functie | Begin |
|---|---|---|
| CLIMB BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 18-06-2025 |
Eerdere bekende functies van Edgar Charles
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-2025 |
Opleiding van Edgar Charles
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
80
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Rockefeller University
 The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Alabama School of Medicine
 The University of Alabama School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
